1 |
NCT00490152 |
Completed |
Microbicides Acceptability Among Sexually Active Young Women |
|
- Behavioral: Automated diary system
|
Observational |
|
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Microbicide use adherence as measured by a computerized phone diary
- Microbicide use adherence as measured by e-mail messages
- Microbicide use adherence as measured by in-depth interviews via teleconference
- (and 6 more...)
|
59 |
Female |
18 Years to 24 Years (Adult) |
NCT00490152 |
ATN 062 |
|
August 2007 |
November 2009 |
November 2009 |
June 22, 2007 |
February 28, 2017 |
|
- University of South Florida College of Medicine
Tampa, Florida, United States - University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States - University Pediatric Hospital
San Juan, Puerto Rico
|
2 |
NCT00490074 |
Completed |
Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers |
|
- Biological: DNA-C
- Biological: NYVAC-C
|
Interventional |
Phase 1 Phase 2 |
- French National Agency for Research on AIDS and Viral Hepatitis
- EuroVacc Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Immunogenicity parameter: presence of CD8/CD4+ T cell responses defined according to internationally agreed criteria for evaluation of IFNgamma ELISPOT assays, in response to env plus at least one of the gag, pol, nef peptide pools
- Safety parameter: grade 3 or above local adverse event, grade 3 or above systemic adverse event, grade 3 or above other clinical or laboratory adverse event,any event attributable to vaccine leading to discontinuation of the immunisation regimen.
- Cellular responses: CD8/CD4+ T cell mean IFNgamma Spot Forming Units (SFU) per million cells across the peptide pools
- (and 6 more...)
|
147 |
All |
18 Years to 55 Years (Adult) |
NCT00490074 |
2006-006141-13 EV03/ANRSVAC20 |
EV03/ANRSVAC20 |
July 2007 |
December 2008 |
October 2009 |
June 22, 2007 |
November 26, 2009 |
|
- Hôpital Henri Mondor
Créteil, France - Centre Hospitalier Universitaire Vaudois CHUV
Lausanne, Switzerland
|
3 |
NCT00486330 |
Completed Has Results |
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir |
|
- Drug: Buprenorphine, Tipranavir and ritonavir
|
Interventional |
Not Applicable |
- Yale University
- Boehringer Ingelheim
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Area Under the Curve of BUP/NLX With TPV/r (h*ng/mL)
|
12 |
All |
18 Years to 60 Years (Adult) |
NCT00486330 |
BUTI |
BUTI |
May 2006 |
May 2007 |
May 2007 |
June 14, 2007 |
November 21, 2012 |
November 21, 2012 |
- Yale University School of Medicine AIDS Program
New Haven, Connecticut, United States
|
4 |
NCT00486408 |
Completed |
Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults |
|
- Biological: MRKAd5 HIV-1 gag/pol/nef
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- HIV Vaccine Trials Network
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Relatedness of different immune response to vaccine
- Features and number of HIV-specific CD4 and CD8 T cells produced in response to the vaccine
- Characterization of different functions of T cells that have responded to the vaccine
- (and 4 more...)
|
35 |
All |
18 Years to 50 Years (Adult) |
NCT00486408 |
HVTN 071 10503 |
|
July 2007 |
September 2008 |
November 2012 |
June 14, 2007 |
June 4, 2015 |
|
- Alabama Vaccine CRS
Birmingham, Alabama, United States - University of Rochester Vaccines to Prevent HIV Infection CRS
Rochester, New York, United States - Vanderbilt Vaccine (VV) CRS
Nashville, Tennessee, United States - Seattle Vaccine and Prevention CRS
Seattle, Washington, United States
|
5 |
NCT00489034 |
Completed |
Engaging Care for HIV-infected Adolescent Females. |
|
- Behavioral: Quantitative Interview
- Behavioral: Ethnographic Interview
- Behavioral: Gender Interview
|
Observational |
|
- University of North Carolina, Chapel Hill
- National Institute of Mental Health (NIMH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Engagement in Care among Index Participants
- Medication Adherence
- Sexual Risk Behaviors
- Substance Use
|
178 |
Female |
13 Years to 23 Years (Child, Adult) |
NCT00489034 |
ATN 009 1R01DA014706-01 |
|
July 2003 |
December 2010 |
December 2010 |
June 21, 2007 |
March 6, 2017 |
|
- Universtiy of Southern California
Los Angeles, California, United States - University of Miami, School of Medicine
Miami, Florida, United States - Stroger Hospital of Cook County
Chicago, Illinois, United States - (and 2 more...)
|
6 |
NCT00483483 |
Completed |
Project HERMITAGE: HIV Prevention in Hospitalized Russian Drinkers |
|
- Behavioral: Individual and group HIV risk behavior counseling sessions
- Behavioral: health education and support group
|
Interventional |
Not Applicable |
- Boston Medical Center
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of unprotected sex acts, unclean drug injections, and sexually transmitted infections (by urinalysis)
- Percentage of protected sex episodes, percentage of unprotected sex episodes Multiple drug partners, Number of sexually transmitted infections (by self report), Alcohol consumption, Disclosure of HIV serostatus
|
700 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00483483 |
H-25082 R01AA016059 |
|
October 2007 |
July 2011 |
March 2012 |
June 7, 2007 |
July 21, 2017 |
|
- City Drug Addiction Center
St. Petersburg, Russian Federation - Pavlov State Medical University and Botkin Infectious Disease Hospital
St. Petersburg, Russian Federation - St. Petersburg AIDS Center
St. Petersburg, Russian Federation
|
7 |
NCT00480350 |
Unknown † |
RiSolubles™, the Soluble Fraction of Rice Bran for HIV-Infected Patients |
|
- Behavioral: rice based food supplement
|
Interventional |
Phase 2 |
- Hadassah Medical Organization
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary endpoint will be an increment of CD4+ cells by a mean of 25% or increase of 100 cells/ mm3 at week 24 in the treatment group
- The proportion with virologic response defined as a plasma HIV-1 reduction of 1 log at week 24
|
140 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00480350 |
shah1HMO-CTIL |
|
September 2007 |
|
January 2009 |
May 30, 2007 |
September 5, 2007 |
|
- Hadassah Medical Organization
Jerusalem, Israel
|
8 |
NCT00482027 |
Completed |
Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine |
|
|
Interventional |
Phase 1 |
- International AIDS Vaccine Initiative
- Targeted Genetics Corporation
- Children's Hospital of Philadelphia
- Nationwide Children's Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Safety of one or two doses of tgAAC09
- Immunogenicity
|
80 |
All |
18 Years to 50 Years (Adult) |
NCT00482027 |
A001 |
A001 |
December 2003 |
December 2006 |
January 2007 |
June 4, 2007 |
January 16, 2013 |
|
- SGS Biopharma
Antwerpen, Belgium - St. Pierre University Hospital
Brussels, Belgium - Univeristy of Bonn
Bonn, Germany - (and 2 more...)
|
9 |
NCT00491556 |
Completed Has Results |
Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r) |
|
- Procedure: Early Initiation of Highly Active Anti-Retroviral Therapy
- Procedure: Standard Care
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Difference in CD4+ T Cell Percentage Between Week 0 and Week 48
- Difference in CD4+ T Cell Percentage Between Week 48 and Week 152
- Difference in CD4+ T Cell Count Between Week 0 and Week 48
- (and 49 more...)
|
102 |
All |
18 Years to 24 Years (Adult) |
NCT00491556 |
ATN 061 |
|
October 2007 |
June 2013 |
June 2013 |
June 26, 2007 |
March 29, 2017 |
June 24, 2016 |
- Children's Hopsital of Los Angeles
Los Angeles, California, United States - University of Southern California - IMPAACT Site
Los Angeles, California, United States - University of California at San Francisco
San Francisco, California, United States - (and 20 more...)
|
10 |
NCT00488059 |
Terminated Has Results |
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients |
|
- Drug: enfuvirtide [Fuzeon]
- Drug: Optimized background ARV
- Drug: Integrase inhibitor
|
Interventional |
Phase 4 |
- Hoffmann-La Roche
- Trimeris
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients in Phase I of the Study With a Confirmed HIV-1 RNA Viral Load ≤ 50 Copies/mL
- Number of Patients in Phase II of the Study With HIV-1 RNA ≤ 50 Copies/mL at Week II-16
- Virologic Response Over Time in Phase I of the Study
- (and 4 more...)
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT00488059 |
ML20837 |
AMICI |
June 2007 |
October 2008 |
October 2008 |
June 19, 2007 |
July 22, 2011 |
June 29, 2011 |
- Hobson City, Alabama, United States
- Phoenix, Arizona, United States
- Los Angeles, California, United States
- (and 40 more...)
|
11 |
NCT00485264 |
Completed Has Results |
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents |
|
- Drug: Raltegravir poloxamer film coated tablet
- Drug: Raltegravir chewable tablet
- Drug: Raltegravir oral granules for suspension (20 mg/mL)
|
Interventional |
Phase 1 Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Grade 3 or 4 Adverse Events (AEs)
- Number of Participants Terminated From Treatment Due to Suspected Adverse Drug Reaction (SADR) Attributable to the Study Medication
- Number of Participants Who Died
- (and 7 more...)
|
153 |
All |
up to 18 Years (Child, Adult) |
NCT00485264 |
P1066 10495 IMPAACT P1066 |
|
September 17, 2007 |
June 3, 2013 |
May 18, 2017 |
June 12, 2007 |
March 29, 2018 |
December 22, 2014 |
- Usc La Nichd Crs
Alhambra, California, United States - University of California, UC San Diego CRS
La Jolla, California, United States - Children's Hospital of Los Angeles NICHD CRS
Los Angeles, California, United States - (and 39 more...)
|
12 |
NCT00479141 |
Completed |
A Cluster-Randomized Intervention Trial to Improve Quality of Life for HIV-Infected Individuals in Anhui, China |
|
- Behavioral: HIV skills training
- Behavioral: Popular Opinion Leaders training
|
Interventional |
Not Applicable |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- Medical Outcomes Study HIV Health Survey (MOS-HIV) score in HIV infected participants
- Level of stigma among community members, including HIV knowledge
|
3199 |
All |
18 Years and older (Adult, Senior) |
NCT00479141 |
CIPRA CH 002B |
|
March 2006 |
July 2007 |
December 2008 |
May 28, 2007 |
March 27, 2009 |
|
- Fuyang CDC Office
Beijing, China
|
13 |
NCT00480792 |
Completed |
Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients |
|
- Biological: GenHevac B Pasteur
|
Interventional |
Phase 3 |
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- MCM Vaccines B.V.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- HIV-infected patients who seroconvert in the first two months after the last vaccination. Seroconversion is defined as antibodies AbHBs titers equal or above 10 mUI per ml.
- According to the vaccine administration (IM or ID) comparison of AbHBs titers,permanence of the humoral response,intensity of clinical and biological events and predicting factors related to seroconversion
|
437 |
All |
18 Years and older (Adult, Senior) |
NCT00480792 |
2006-003940-50 ANRS HB 03 VIHVAC-B |
VIHVAC-B |
June 2007 |
December 2008 |
September 2012 |
May 31, 2007 |
July 23, 2013 |
|
- Hopital Cochin CIC de vaccinologie
Paris, France
|
14 |
NCT00487188 |
Completed Has Results |
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience |
|
- Drug: Enfuvirtide
- Drug: Highly active antiretroviral treatment (HAART)
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Viral Suppression: HIV-1 RNA < 50 Copies/mL During the Induction Phase
- Time to Achieving HIV-1 RNA < 50 Copies/mL During the Induction Phase
- Number of Participants With Viral Suppression HIV-1 RNA < 400 Copies/mL During the Induction Phase
- (and 11 more...)
|
47 |
All |
18 Years and older (Adult, Senior) |
NCT00487188 |
MV18406 |
INTENSE |
November 2005 |
November 2007 |
April 2008 |
June 15, 2007 |
August 13, 2015 |
September 2, 2011 |
- Cleveland, Ohio, United States
- Austin, Texas, United States
- Dallas, Texas, United States
- (and 36 more...)
|
15 |
NCT00489385 |
Completed |
An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals |
|
- Drug: Albinterferon
- Drug: Ribavirin
- Drug: Albuferon
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of two doses of Albinterferon alpha 2b with ribavirin.
- Histologic, virologic responses to Albinterferon alpha 2b and ribavirin
|
41 |
All |
18 Years and older (Adult, Senior) |
NCT00489385 |
070001 07-I-0001 |
|
June 18, 2007 |
March 15, 2011 |
March 15, 2011 |
June 21, 2007 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
16 |
NCT00484627 |
Completed |
Effects of Creatine and Resistance Exercise Training in People With HIV Infection |
|
- Procedure: Use of creatine monohydrate (a dietary supplement)
- Behavioral: Progressive resistance exercise training
|
Interventional |
Phase 2 |
- National Center for Complementary and Integrative Health (NCCIH)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Supportive Care
|
- Muscle strength
- Muscle size
- Muscle energetics
- (and 3 more...)
|
43 |
All |
18 Years to 65 Years (Adult) |
NCT00484627 |
R01AT000491-01 |
|
August 2001 |
|
October 2003 |
June 11, 2007 |
June 11, 2007 |
|
- San Francisco General Hospital
San Francisco, California, United States
|
17 |
NCT00479999 |
Completed |
Phase 1 Safety Study of Two Experimental HIV Vaccines |
- AIDS Vaccines
- HIV Infections
- HIV-1
|
- Drug: VRC-HIVADV027-00-VP
- Drug: VRC-HIVADV038-00-VP
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Safety (local and systemic reactogenicity, lab tests, AEs)
- Immunogenicity (cellular and humoral immune function assays)
|
35 |
All |
18 Years to 50 Years (Adult) |
NCT00479999 |
070167 07-I-0167 |
|
May 24, 2007 |
May 5, 2014 |
May 5, 2014 |
May 30, 2007 |
April 20, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
18 |
NCT00480558 |
Completed |
A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both |
|
|
Interventional |
Phase 1 |
- University of Oxford
- University of Cape Town
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To assess the safety of a single intradermal injection of 5 x 107p.f.u. MVA85A.
- To assess the effect of a single vaccination with MVA85A in asymptomatic participants who are infected with M.Tb or HIV or both on the immune response, both to antigen 85A (the antigen in the vaccine) and to ESAT6/CFP10 antigens (M.tb specific).
|
48 |
All |
21 Years to 50 Years (Adult) |
NCT00480558 |
TB011 |
|
July 2007 |
January 2011 |
January 2011 |
May 31, 2007 |
March 28, 2011 |
|
- University Cape Town
Cape Town, South Africa
|
19 |
NCT00488995 |
Withdrawn |
Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients |
- Human Immunodeficiency Virus
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single
- Primary Purpose: Treatment
|
- Maximum reduction in HIV plasma RNA between Baseline and Week 12 Maximum increase in CD4+ cell count between Baseline and Week 12
- Change from baseline in CD8+ cell count, CD4/CD8, and lymphocyte phenotype through Week 12
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT00488995 |
A3671029 |
|
July 2007 |
|
|
June 20, 2007 |
March 11, 2015 |
|
|
20 |
NCT00483054 |
Completed |
Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin |
- HIV Infections
- Tuberculosis
|
- Drug: efavirenz
- Drug: nevirapine
|
Interventional |
Phase 3 |
- Bamrasnaradura Infectious Diseases Institute
- Mahidol University
- Chulalongkorn University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To compare proportion of patients who achieved undetectable plasma HIV-1RNA< 50 copies/mL at 48 weeks after initiation of antiretroviral treatment between the 2 groups
- to compare CD4 response at 48, 96 and 144 weeks after initiation of antiretroviral treatment, to compare adverse drugs reaction between the 2 groups
|
142 |
All |
18 Years to 60 Years (Adult) |
NCT00483054 |
210041000824904203 |
N2R |
January 2007 |
December 2008 |
December 2010 |
June 6, 2007 |
November 22, 2011 |
|
- Bamrasnaradura Infectious Diseases Institute
Nonthaburi, Thailand
|
21 |
NCT00477321 |
Completed |
Safety Study of IL-7 in HIV-infected Patients (Inspire) |
- HIV Infections
- Lymphopenia
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Changes in T cell counts, changes in T cell proliferation, changes in expression of CD127 on T cells
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT00477321 |
CLI-107-06 |
|
May 2007 |
October 2009 |
July 2010 |
May 23, 2007 |
October 18, 2012 |
|
- University of Miami School of Medicine
Miami, Florida, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Case Western Reserve University
Cleveland, Ohio, United States - (and 5 more...)
|
22 |
NCT00478231 |
Completed Has Results |
Multicenter, Safety Study Of Maraviroc |
- Acquired Immunodeficiency Syndrome
- HIV Infection
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Number of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities
- Number of Participants With Treatment Emergent Malignancies
- (and 10 more...)
|
209 |
All |
18 Years and older (Adult, Senior) |
NCT00478231 |
A4001063 |
|
July 2007 |
August 2010 |
September 2010 |
May 24, 2007 |
September 9, 2011 |
August 8, 2011 |
- Pfizer Investigational Site
Salvador, BA, Brazil - Pfizer Investigational Site
Brasilia, DF, Brazil - Pfizer Investigational Site
Belo Horizonte, MG, Brazil - (and 13 more...)
|
23 |
NCT00482963 |
Completed |
A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication |
- HIV Infections
- Contraception
- Pharmacokinetics
|
- Drug: levonorgestrel, efavirenz
|
Interventional |
Phase 1 |
- University of Colorado, Denver
- The Miriam Hospital
- University of Washington
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The change in Plan B (levonorgestrel) Area under the Concentration Time Curve (AUC12) prior to and during steady state efavirenz
- Pharmacokinetic parameters of levonorgestrel prior to and during steady state efavirenz
- Frequency of common levonorgestrel-associated adverse events prior to and during steady-state efavirenz
- (and 2 more...)
|
24 |
Female |
18 Years to 45 Years (Adult) |
NCT00482963 |
06-1178 |
|
May 2007 |
December 2008 |
December 2008 |
June 6, 2007 |
July 15, 2013 |
|
- University of Colorado Health Sciences Center
Denver, Colorado, United States - The Miriam Hospital
Providence, Rhode Island, United States
|
24 |
NCT00489528 |
Completed |
Growth Hormone in the Treatment of HIV-Associated Wasting |
- HIV Infections
- HIV Wasting Syndrome
|
- Drug: Somatropin; Recombinant human growth hormone (r hGH)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- To confirm the clinical efficacy of Serostim compared with placebo, based on an endpoint of exercise function change.
- To establish an optimal dose of Serostim, based on the endpoint of lean body mass (LBM) change.
|
|
All |
18 Years and older (Adult, Senior) |
NCT00489528 |
9037 |
|
July 1997 |
|
March 2002 |
June 21, 2007 |
October 22, 2013 |
|
|
25 |
NCT00490412 |
Completed |
Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection |
|
- Dietary Supplement: Vitamin D supplement
- Other: Placebo
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- To compare the change in renal tubular reabsorption of phosphate and markers of bone turnover.
- To measure the safety of 50,000 IU dose of vitamin D3
- To measure the relationship of vitamin D plasma concentrations to renal tubular reabsorption of phosphate and markers of bone turnover
- (and 2 more...)
|
207 |
All |
18 Years to 24 Years (Adult) |
NCT00490412 |
ATN 063 |
|
December 2007 |
January 2010 |
January 2010 |
June 22, 2007 |
February 28, 2017 |
|
- Children's Hopsital of Los Angeles
Los Angeles, California, United States - University of California at San Francisco
San Francisco, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - (and 12 more...)
|
26 |
NCT00481390 |
Completed |
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients |
- Infection, Human Immunodeficiency Virus I
- HIV Infection
- HIV-1 Infection
|
- Procedure: Cheek cells sample
- Procedure: Blood sample
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Prevalence of HLA-B*5701 in European HIV-1 population
- Prevalence of HLA-B*5701 in major European ethnotypes
|
1110 |
All |
18 Years and older (Adult, Senior) |
NCT00481390 |
CNA110329 |
|
June 2007 |
December 2007 |
December 2007 |
June 1, 2007 |
June 8, 2011 |
|
- GSK Investigational Site
Helsinki, Finland - GSK Investigational Site
Dublin, Ireland - GSK Investigational Site
Alkmaar, Netherlands - (and 17 more...)
|
27 |
NCT00483392 |
Completed |
Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients |
|
- Drug: metformin, rosiglitazone
|
Interventional |
Not Applicable |
- University Medical Centre Ljubljana
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- fasting plasma glucose, basal insulin levels
- insulin resistance, beta cell function
|
|
Male |
18 Years to 60 Years (Adult) |
NCT00483392 |
J3-3545 Slovenia grant J3-3545 |
|
|
|
|
June 7, 2007 |
June 7, 2007 |
|
- Department of Endocrinology, Diabetes and Metabolic diseases
Ljubljana, Slovenia
|